Related Experiment Video
Updated: Mar 4, 2026

Percutaneous Contrast Echocardiography-guided Intramyocardial Injection and Cell Delivery in a Large Preclinical Model
Published on: January 21, 2018
Ischemic Heart Disease: Special Considerations in Cardio-Oncology
Dana Elena Giza1, Fernando Boccalandro2, Juan Lopez-Mattei1
1The Department of Cardiology, The University of Texas MD Anderson Cancer Center, 1400 Pressler Street, Houston, TX, 77030, USA.
Insights
Managing ischemic heart disease in cancer patients is crucial for successful cancer treatment and survival. This review highlights the complexities and strategies for optimizing cardiovascular care alongside cancer therapy.
Area of Science:
- Oncology
- Cardiology
- Internal Medicine
Background:
- Cardiovascular diseases (CVD) and cancer significantly impact patient outcomes.
- Ischemic heart disease (IHD) is an emerging concern in cancer patients, whether pre-existing or therapy-induced.
- Cancer-related comorbidities complicate CVD management.
Purpose of the Study:
- To review current knowledge on managing IHD in cancer patients.
- To focus on the challenges in managing cardiovascular disease in this population.
Main Methods:
- Literature review of current management strategies for IHD in cancer patients.
- Analysis of complexities arising from cancer and its comorbidities.
Main Results:
- Effective management of IHD is vital for successful cancer treatment.
- Cancer and its associated conditions (e.g., bleeding risks, thrombosis) present unique challenges.
Conclusions:
- Optimizing IHD management in cancer patients improves malignancy treatment and reduces cardiovascular mortality.
- Addressing the interplay between cancer and CVD is essential for comprehensive patient care.
Opinion Statement:
The interplay and balance between the competing morbidity and mortality of cardiovascular diseases and cancer have a significant impact on both short- and long-term health outcomes of patients who survived cancer or are being treated for cancer. Ischemic heart disease in patients with cancer or caused by cancer therapy is a clinical problem of emerging importance. Prompt recognition and optimum management of ischemic heart disease mean that patients with cancer can successfully receive therapies to treat their malignancy and reduce morbidity and mortality due to cardiovascular disease. In this sense, the presence of cancer and cancer-related comorbidities (e.g., thrombocytopenia, propensity to bleed, thrombotic status) substantially complicates the management of cardiovascular diseases in cancer patients. In this review, we will summarize the current state of knowledge on the management strategies for ischemic disease in patients with cancer, focusing on the challenges encountered when addressing these complexities.
Related Concept Videos
Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VI: Nursing Management
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Exercise and Cardiovascular Response
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Cardiomyopathy III: Hypertrophic Cardiomyopathy

